TB-500: Discovery and Regulatory History

Introduction

The research history of TB-500 (Ac-LKKTETQ) is embedded within a broader scientific narrative that began in the 1960s with the systematic investigation of the thymus gland as an endocrine organ. Understanding TB-500 as a research compound requires tracing the isolation of the thymosin peptide family, the identification of thymosin beta-4 (Tβ4) as the principal cytoplasmic actin-sequestering peptide, the mapping of the LKKTETQ active site, and the regulatory trajectory of both the parent peptide and its synthetic fragment. This article presents that history chronologically, drawing on peer-reviewed and regulatory primary sources. A parallel discovery timeline for another member of the healing and regenerative peptide cluster, BPC-157, illustrates how gastric-origin and thymic-origin peptides reached similar research contexts through distinct scientific lineages.

Discovery Period: Thymosin Research and the Thymus (1960s–1981)

The scientific interest in thymic peptides as potential regulatory molecules originated with work at Albert Einstein College of Medicine in New York beginning in the early 1960s, in the laboratory of Abraham White, and subsequently developed by Allan L. Goldstein, who relocated his laboratory to the University of Texas and later to the George Washington University School of Medicine. Early publications by Goldstein's group characterized thymosin as a partially purified thymic fraction capable of inducing terminal deoxynucleotidyl transferase (TdT) activity in immature thymocyte populations, framing these peptides as immune cell developmental signals [1].

The isolation and chemical characterization of individual thymosin polypeptides followed through the 1970s. In 1981, Low, Hu, and Goldstein published the complete amino acid sequence of thymosin beta-4 (Tβ4) in the Proceedings of the National Academy of Sciences USA, describing a 43-amino-acid peptide isolated from calf thymus [2]. This paper established the primary structure of Tβ4 and marked the compound's formal entry into the scientific literature under its current designation.

Early Research: Identifying the Cytoskeletal Role (1982–1995)

Initial characterization framed Tβ4 as a thymic hormone associated with lymphocyte development. That interpretation was substantially expanded through the late 1980s and early 1990s, when multiple groups identified Tβ4 at high concentrations in non-lymphoid tissues and in cell types not typically associated with thymic signaling.

Hannappel, Xu, Morgan, Hempstead, and Horecker published work in Proceedings of the National Academy of Sciences USA in 1982 demonstrating that Tβ4 was present not only in thymus but in spleen, brain, lung, liver, and heart muscle of rats and mice, with particularly high concentrations in peritoneal macrophages [3]. This ubiquitous tissue distribution was inconsistent with a purely thymic endocrine role and prompted a re-examination of the peptide's function.

The pivotal mechanistic reinterpretation was published by Safer, Elzinga, and Nachmias in Journal of Biological Chemistry in 1991. Their work identified Tβ4 as identical to an actin-sequestering peptide ("Fx peptide") previously characterized in a separate biochemical line of research, and demonstrated 1:1 stoichiometric G-actin binding that inhibited polymerization [4]. This finding established Tβ4 as the principal cytoplasmic buffer for unpolymerized actin in human polymorphonuclear leukocytes, resolving a longstanding cell biology question and redirecting the field toward cytoskeletal biology as the primary interpretive framework.

Through the early to mid-1990s, Safer and colleagues published systematic fragment-mapping studies identifying the LKKTETQ sequence (residues 17–23) as the minimum sequence required for substantial actin-sequestering activity in biochemical assays [5] — laying the intellectual foundation for the TB-500 fragment.

Regulatory Milestones and Clinical Development (2000–present)

Interest in therapeutic applications of Tβ4 developed in parallel with the mechanistic research. The corneal wound context attracted early attention, with studies by Sosne, Szliter, Kleinman, and colleagues published in 2001 and 2002 reporting that topical Tβ4 was associated with wound closure in rabbit corneal abrasion models [6].

RegeneRx Biopharmaceuticals, Inc. — a company founded with scientific input from Allan Goldstein and focused on clinical development of Tβ4 — pursued formal regulatory evaluation of two formulations: RGN-259 (ophthalmic) and RGN-352 (injectable). RegeneRx submitted Investigational New Drug (IND) applications to the FDA and conducted Phase 2 clinical trials for both indications.

A Phase 2 trial of RGN-259 for dry eye disease, reported in Cornea in 2015 by Sosne, Dunn, and Kim, enrolled nine patients in a randomized, double-masked, placebo-controlled design and reported statistically significant differences on composite dry eye endpoints, with no serious adverse events attributed to the compound [7]. This result supported advancement to Phase 3.

A Phase 3 trial of RGN-259 for neurotrophic keratopathy was published in Clinical Ophthalmology in 2022 by Bonini, Sheha, Hamrah, and colleagues, reporting greater proportional healing in the active arm versus placebo over four weeks [8] — the most advanced clinical evaluation of a Tβ4-derived compound published to date.

For cardiac indications, a Phase 2 trial of injectable RGN-352 in acute myocardial infarction patients (NCT01311518) was conducted by RegeneRx. The compound was reported as tolerated; the cardiac functional outcomes observed in preclinical models were not replicated in that trial population. This outcome informed the field's understanding of the preclinical-to-clinical translational pathway for this compound class — a challenge common across cardiac regeneration research. Neither formulation has received FDA approval as of publicly available records.

Emergence of TB-500 as a Research Compound and Regulatory Context

The synthetic Ac-LKKTETQ fragment designated TB-500 entered the commercial research peptide market independently of the RegeneRx clinical programs. TB-500 preparations are not associated with any IND application or controlled clinical development program. The fragment's appearance as a commercial research reagent coincided with the broader expansion of the synthetic peptide research supply market in the 2000s.

The anti-doping research community engaged with TB-500 beginning in the early 2010s. Görgens, Guddat, Schänzer, and Thevis published the synthesis and structural characterization of N-acetyl-LKKTETQ in Drug Testing and Analysis in 2012, establishing a reference standard and confirming the molecular identity of the compound found in commercial TB-500 preparations [9]. Weidemann and colleagues subsequently published validated LC-MS/MS detection methods for Ac-LKKTETQ in equine urine and plasma in 2013, reporting detection limits at sub-nanogram-per-milliliter concentrations [10].

The World Anti-Doping Agency (WADA) listed thymosin beta-4 and its derivatives — including TB-500 — on the WADA Prohibited List under the S2 category (Peptide Hormones, Growth Factors, Growth Factor Mimetics, and Related Substances), as growth factor modulators [11]. This prohibition applies to both human and equine competition, in-competition and out-of-competition. Researchers requiring verified TB-500 from SpartaLabs can review the available analytical documentation on the product page.

Current Research Landscape

As of available published records, research on thymosin beta-4 and the LKKTETQ fragment continues across several domains. Clinical evaluation of RGN-259 extended to Phase 3, with results published in 2022. Basic science investigation of the Tβ4/actin axis in cardiac regeneration, neurological contexts, and corneal biology remained active through the peer-reviewed literature of 2023–2025.

A 2025 study on engineered tandem thymosin peptides published in Translational Vision Science and Technology illustrated the continuing scientific evolution of Tβ4-derived research tools [12], as investigators moved beyond the intact parent sequence toward modified variants with altered structural properties — a trajectory that will continue to shape the research landscape for compounds of this class.

TB-500 itself remains a research-use-only compound with no approved therapeutic indication. The full-length parent peptide Tβ4, under its clinical designations, remains the subject of published clinical investigation for specific ophthalmic indications, as documented in the research article in this library. Analytical and purity specifications for research-grade Ac-LKKTETQ are described in the TB-500 sourcing and quality article.

References

1. Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA. 1972;69(7):1800–1803. PMID: 4624140. https://pubmed.ncbi.nlm.nih.gov/4624140/

2. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162–1166. PMID: 6940133. https://pubmed.ncbi.nlm.nih.gov/6940133/

3. Hannappel E, Xu S, Morgan J, Hempstead J, Horecker BL. Thymosin beta 4: a ubiquitous peptide in rat and mouse tissues. Proc Natl Acad Sci USA. 1982;79(7):2172–2175. PMC346152. https://pmc.ncbi.nlm.nih.gov/articles/PMC346152/

4. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032. PMID: 1999398. https://pubmed.ncbi.nlm.nih.gov/1999398/

5. Safer D, Chowrashi PK. Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay. Cell Motil Cytoskeleton. 1993;25(4):329–335. PMID: 8471179. https://pubmed.ncbi.nlm.nih.gov/8471179/

6. Sosne G, Szliter EA, Barrett R, Kleinman HK, Bhattacharya B. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293–299. PMID: 11950239. https://pubmed.ncbi.nlm.nih.gov/11950239/

7. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. PMID: 25826322. https://pubmed.ncbi.nlm.nih.gov/25826322/

8. Bonini S, Sheha H, Hamrah P, et al. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked Phase III clinical trial. Clin Ophthalmol. 2022;16:4295–4310. PMC9820614. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/

9. Görgens C, Guddat S, Schänzer W, Thevis M. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(11):871–876. PMID: 22962027. https://pubmed.ncbi.nlm.nih.gov/22962027/

10. Weidemann S, Görgens C, Dib J, Düe M, Guddat S, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Drug Test Anal. 2013;5(6):441–449. PMID: 23084823. https://pubmed.ncbi.nlm.nih.gov/23084823/

11. World Anti-Doping Agency. The Prohibited List 2024. Montreal: WADA; 2024. https://www.wada-ama.org/en/prohibited-list

12. Wu H, Kim J, Kwon M, et al. Engineered tandem thymosin peptide promotes corneal wound healing. Transl Vis Sci Technol. 2025;14(1):16. PMID: 41235866. https://pubmed.ncbi.nlm.nih.gov/41235866/